- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05812755
SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery (SOLSTICE)
The Effects of Soluble Guanylyl Cyclase Stimulation on Perioperative Vascular Reactivity and Organ Injury in Cardiac Surgery
The goal of this mechanistic clinical trial is to learn about the effects of medications called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and brain injury in patients having heart surgery. The main questions it aims to answer are:
- Does soluble guanylyl cyclase stimulation improve blood vessel function compared to placebo?
- Does soluble guanylyl cyclase stimulation decrease markers of kidney injury and brain injury compared to placebo?
Participants will be randomized to a soluble guanylyl cyclase stimulator called vericiguat or placebo, and researchers will compare vascular function and markers of brain and kidney injury to see if vericiguat improves vascular function and reduces markers of injury.
This will provide important information to determine the underlying reasons that patients have some kidney and brain function problems after having heart surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37204
- Recruiting
- Vanderbilt University Medical Center
-
Contact:
- Marcos G Lopez, MD
- Phone Number: 615-936-5894
- Email: marcos.g.lopez@vumc.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years
- Elective open-heart surgery, defined as surgery on the heart or aorta that requires sternotomy or thoracotomy
Exclusion Criteria:
- Intolerance to vericiguat
- Use of other soluble guanylyl cyclase stimulators or current use of phosphodiesterase-5 inhibitors
- Pregnancy or breast feeding. Pregnancy will be excluded in women of child-bearing potential by a urine or serum beta hcg test
- Renal replacement therapy within 30 days prior to screening
- Estimated glomerular filtration rate <15 ml/min per 1.73 m2 per Chronic Kidney Disease Epidemiology collaboration (CKD-EPI) equation at time of screening
- Systolic blood pressure less than 120 mmHg at the time of screening
- Prior kidney transplantation
- History of significant liver dysfunction (defined as Child-Pugh class C)
- Surgery scheduled to be performed with circulatory arrest
- Surgery scheduled to correct a major congenital heart defect
- Extracorporeal membrane oxygenation (ECMO) prior to surgery
- Active systemic infection or surgery for infectious endocarditis
- Ventricular assist device or intraaortic balloon pump support prior to surgery
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vericiguat
10 mg vericiguat administered orally once daily for three days (through day of surgery)
|
Vericiguat 10 mg administered orally starting 2 days prior to heart surgery through the day of surgery
|
Placebo Comparator: Placebo
placebo administered orally once daily for three days (through day of surgery)
|
Matched placebo administered orally starting 2 days prior to heart surgery through the day of surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brachial artery flow-mediated dilation
Time Frame: Day of surgery
|
Percent change in brachial artery diameter from baseline to maximum post-forearm ischemia adjusted for shear-rate (Aim 1 primary outcome).
|
Day of surgery
|
Ex vivo vascular relaxation
Time Frame: Day of surgery
|
Ex vivo arterial relaxation (percent) in participants with available vascular tissue (Aim 1 primary outcome)
|
Day of surgery
|
Ubiquitin C-terminal hydrolase L1 (UCHL1) plasma concentration
Time Frame: Enrollment through postoperative day 2
|
UCHL1 will be measured in plasma to quantify effects of vericiguat vs. placebo on neuronal injury (Aim 2 primary neuronal outcome)
|
Enrollment through postoperative day 2
|
Neutrophil gelatinase associated lipocalin (NGAL) urine concentration
Time Frame: Enrollment through postoperative day 2
|
NGAL will be measured in urine to quantify effects of vericiguat vs. placebo on markers of renal injury (Aim 2 primary renal outcome)
|
Enrollment through postoperative day 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phosphorylated vasodilator stimulated phosphoprotein (phospho-VASP)
Time Frame: Enrollment through postoperative day 2
|
Soluble guanylyl cyclase stimulation will be further quantified as arterial phospho-VASP/VASP ratio(Aim 1 secondary outcome)
|
Enrollment through postoperative day 2
|
Endothelial barrier breakdown - claudin-5
Time Frame: Enrollment through postoperative day 2
|
Endothelial barrier breakdown will be quantified as plasma concentration of claudin-5 (Aim 1 secondary outcome)
|
Enrollment through postoperative day 2
|
Endothelium mediated inflammation and coagulation - plasminogen activator inhibitor-1 (PAI-1)
Time Frame: Enrollment through postoperative day 2
|
Endothelium mediated inflammation and coagulation will be quantified as plasma concentration of PAI-1 (Aim 1 secondary outcome)
|
Enrollment through postoperative day 2
|
Endothelial Activation - intercellular adhesion molecule 1 (ICAM1)
Time Frame: Enrollment through postoperative day 2
|
Endothelial activation will be quantified as plasma concentrations of ICAM1 (Aim 1 secondary outcome)
|
Enrollment through postoperative day 2
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory clinical outcome: serum creatinine
Time Frame: Postoperative day 0 up to 1 year postoperatively (e.g., approximately 1 year after the day of surgery)
|
Serum creatinine
|
Postoperative day 0 up to 1 year postoperatively (e.g., approximately 1 year after the day of surgery)
|
Exploratory clinical outcome: Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury (AKI)
Time Frame: Postoperative day 0 up to 1 year postoperatively (e.g., approximately 1 year after the day of surgery)
|
Incidence of KDIGO creatinine criteria AKI
|
Postoperative day 0 up to 1 year postoperatively (e.g., approximately 1 year after the day of surgery)
|
Exploratory clinical outcome: delirium
Time Frame: Postoperative day 0 to 10 days postoperatively
|
Incidence (percent of participants) with a positive delirium exam measured using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU).
|
Postoperative day 0 to 10 days postoperatively
|
Exploratory clinical outcome: delirium severity
Time Frame: Postoperative day 0 to 10 days postoperatively
|
Severity of delirium measured using the CAM-ICU-7 score for at least 3 days postoperatively up to 10 days postoperatively for participants who remain in ICU.
This is a 7 point scale score with higher scores indicating higher severity of delirium
|
Postoperative day 0 to 10 days postoperatively
|
Exploratory clinical outcome: Infection
Time Frame: Postoperative day 0 to 10 days postoperatively
|
Infection defined as initiation of antibiotics postoperatively not part of perioperative antibiotic prophylaxis.
|
Postoperative day 0 to 10 days postoperatively
|
Exploratory clinical outcome: Respiratory failure
Time Frame: Postoperative day 0 to hospital discharge (e.g., up to approximately 30 days following surgery)
|
Respiratory failure defined as the need for mechanical ventilation
|
Postoperative day 0 to hospital discharge (e.g., up to approximately 30 days following surgery)
|
Exploratory clinical outcome: Thrombocytopenia
Time Frame: Postoperative day 0 to hospital discharge(e.g., up to approximately 30 days following surgery)
|
Thrombocytopenia defined at platelet count less than 50,000
|
Postoperative day 0 to hospital discharge(e.g., up to approximately 30 days following surgery)
|
Exploratory clinical outcome: Arrythmia
Time Frame: Postoperative day 0 to hospital discharge (e.g., up to approximately 30 days following surgery)
|
Arrhythmia defined the onset of new atrial or ventricular dysrhythmia
|
Postoperative day 0 to hospital discharge (e.g., up to approximately 30 days following surgery)
|
Exploratory clinical outcome: Intensive care unit (ICU) length of stay
Time Frame: Postoperative day 0 to until discharge from the ICU (e.g. up to approximately 10 days following surgery)
|
ICU length of stay in days
|
Postoperative day 0 to until discharge from the ICU (e.g. up to approximately 10 days following surgery)
|
Exploratory clinical outcome: Hospital length of stay
Time Frame: Postoperative day 0 to hospital discharge (e.g., up to approximately 30 days following surgery)
|
Hospital length of stay in days
|
Postoperative day 0 to hospital discharge (e.g., up to approximately 30 days following surgery)
|
Exploratory clinical outcome: Death
Time Frame: Postoperative day 0 to one year postoperatively
|
Mortality measured up to one year
|
Postoperative day 0 to one year postoperatively
|
Exploratory cognitive status outcome: Telephone interview for cognitive status
Time Frame: 6 months postoperatively
|
Six-month follow-up (Telephone Interview for Cognitive Status) obtained by phone interview.
Maximum score is 41 and lower score indicates worse cognitive function.
|
6 months postoperatively
|
Exploratory functional status outcome: Katz Activities of Daily Living (ADL) assessment
Time Frame: 6 months postoperatively
|
Activities of daily living will be assessed with the Katz ADL assessment via phone interview.
This survey assesses independence in 6 activities, and will be summarized as the average number of independent activities.
|
6 months postoperatively
|
Exploratory functional status outcome: Pfeffer functional activities questionnaire
Time Frame: 6 months postoperatively
|
Activities of daily living will be assessed with the Pfeffer functional activities questionnaire via phone interview.
Maximum score is 30.
A score of greater than 9 indicates impaired function and possible cognitive impairment.
|
6 months postoperatively
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Marcos Lopez, MD, Vanderbilt University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 222089
- R01HL164909 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vascular Diseases
-
Terumo Europe N.V.CompletedPeripheral Vascular Disease | Hemostasis | Vascular Closure | Endovascular ProcedureBelgium, France, Germany
-
University Hospital, MontpellierTerminated
-
Alvotech Swiss AGActive, not recruitingChorioretinal Vascular DiseaseGeorgia
-
University of California, IrvineUniversity of Oklahoma; US Department of Veterans Affairs; C. R. Bard; Long Beach...CompletedPeripheral Vascular Disease | Cardiac Catheterization | Vascular Access ComplicationsUnited States
-
AmgenCompletedChorioretinal Vascular DiseaseUnited States
-
Duke UniversityTerminatedRetinal Vascular DiseaseUnited States
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
Regeneron PharmaceuticalsCompletedChorioretinal Vascular DiseaseUnited States
-
Terumo Europe N.V.Terumo Medical CorporationRecruitingPeripheral Vascular Disease | Hemostasis | Vascular Closure | Femoral Artery | Endovascular ProcedureFrance, Germany, Netherlands
Clinical Trials on Vericiguat
-
BayerMerck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCBayer; Duke Clinical Research Institute; Canadian VIGOUR CentreCompletedHeart Failure | Chronic Heart Failure With Reduced Ejection Fraction
-
The First Affiliated Hospital with Nanjing Medical...RecruitingAcute Coronary Syndrome | Heart Failure With Reduced Ejection FractionChina
-
University of Colorado, DenverNot yet recruitingHeart Failure
-
BayerCompletedHeart FailureBelgium, France, Switzerland, United States, Spain, Greece, Japan, Singapore, Austria, Germany, Korea, Republic of, Poland, Denmark, Israel, Netherlands, Taiwan, Bulgaria, Canada, Sweden, Czechia, Australia, Italy, Hungary, United Kingdom
-
BayerCompletedHeart FailureBelgium, France, Spain, Greece, Portugal, Japan, United States, Singapore, Austria, Germany, Korea, Republic of, Poland, Australia, Israel, Netherlands, Switzerland, Taiwan, Bulgaria, Canada, Czechia, Denmark, Hungary, Italy, Sweden, United...
-
BayerActive, not recruitingChronic Heart Failure With Reduced Ejection FractionUnited States
-
BayerCompleted
-
Johns Hopkins UniversityMerck Sharp & Dohme LLCRecruitingMetabolic Syndrome | Coronary Microvascular DysfunctionUnited States
-
BayerRecruitingChronic Heart Failure With Reduced Ejection FractionKorea, Republic of